Discover investment opportunities in Best Microcap Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Microcap Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Microcap Stocks using our Smart AI Filter.
6 stocks found for "Best Microcap Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.68 | ±100.0% | -97.0 | 0.00% | |||
0.45 | ±100.0% | — | 0.00% | |||
0.33 | ±100.0% | -10.0 | 0.00% | |||
0.02 | ±100.0% | — | 0.00% | |||
0.28 | ±100.0% | -10.2 | 0.00% | |||
0.42 | ±73.1% | 12.6 | 1.02% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read moreKULR Technology Group (KULR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read moreQ: How can investors assess the potential growth of TELL in the natural gas sector?
A: TELL, or Tellurian Inc., focuses on natural gas and liquefied natural gas infrastructure. Investors may consider its strategic positions in LNG markets and partnerships. Market conditions, geopolitical factors, and demand for cleaner energy can affect growth prospects.
Q: What are some risks associated with investing in VXRT's biotech ventures?
A: VXRT operates in the volatile biotech sector, facing risks like regulatory approval hurdles, clinical trial results, and potential competition. Investors often evaluate R&D pipelines and partnership deals to gauge risk levels.
Q: In what ways could NNDM appeal to tech-focused investors?
A: NNDM, or Nano Dimension, specializes in additive electronics and 3D-printed electronics. Its appeal may lie in innovative technology and potential applications in various tech industries. However, the company operates in a rapidly evolving market.
Q: How does BBLG's environmental focus potentially benefit its growth strategy?
A: BBLG, engaged in sustainable solutions, may benefit from growing environmental awareness and regulatory shifts promoting eco-friendly products. Its market position in clean technology can be advantageous amid increasing ESG considerations.
Q: What should investors consider when evaluating the stability of SPPI's financial health?
A: SPPI, or Spectrum Pharmaceuticals, faces challenges typical of biotech firms, like funding R&D and achieving drug approvals. Financial indicators such as cash reserves and partnerships might provide insights into its stability.
Q: Can SURF's innovations in the pharmaceutical sector appeal to long-term investors?
A: SURF, a biopharma company, focuses on developing specialized therapies. Long-term investors might find its innovative drug pipeline appealing, though they should weigh this against potential regulatory and market competition challenges.